AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cryo-Cell International Reports Q3 Revenue and Net Income Declines
ByAinvest
Wednesday, Oct 15, 2025 5:11 pm ET1min read
Cryo-Cell International, a cord blood banking company, reported Q3 revenue and net income decline. The company operates through three segments, focusing on cord blood and tissue stem cell collection, processing, and cryogenic storage for family and public use. With approximately 235,000 stored specimens, Cryo-Cell markets its services directly to expectant parents and through healthcare professionals.
Cryo-Cell International, a leading provider of cord blood and tissue stem cell collection, processing, and cryogenic storage services, reported a decline in its third-quarter (Q3) financial results for the period ended August 31, 2025. According to , the company's consolidated revenues decreased to $7.83 million, down from $8.07 million in the same period last year, representing a 3% decrease. Net income for the quarter was $749,000, or $0.09 per share, compared to $1.05 million, or $0.13 per share, in the prior-year quarter, the report added.Cryo-Cell operates through three segments: cord blood and tissue stem cell collection, processing, and cryogenic storage for family and public use. The report noted the company serves approximately 235,000 stored specimens, marketing its services directly to expectant parents and through healthcare professionals.
The revenue decline was primarily attributed to a slight decrease in processing and storage fees, which accounted for $7.87 million of the total revenue. Public banking revenue and product revenue remained relatively stable at $43,000 and $14,000, respectively, the report showed. The company's operational credentials, including FDA registration, cGMP/cGTP compliance, AABB and FACT accreditations, and exclusive rights to PrepaCyte-CB processing, were reaffirmed in the latest filing, the report also stated.
Despite the financial setback, Cryo-Cell continues to maintain its position as a leader in the cord blood banking industry. The company's strategic initiatives, such as the ExtraVault biostorage and distribution solutions, remain in progress. Future financial performance will be closely watched by investors and industry stakeholders.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet